GLP-1 Response
Cross-source consensus on GLP-1 Response from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Evidence quality
Other
Highlighted claims
- Before BARI-STEP, semaglutide 2.4 mg had not been tested in a randomized clinical trial for poor clinical weight response after bariatric surgery. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Baseline meal-stimulated GLP-1 change was not significantly associated with percentage weight loss at 68 weeks. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Prior liraglutide trials supported GLP-1 receptor agonist therapy after bariatric surgery. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Lower meal-stimulated circulating GLP-1 has been associated with poorer bariatric weight-loss responses. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- The trial suggests pharmacological GLP-1 receptor agonism may override mechanisms related to blunted endogenous GLP-1 response. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial